OnCore Login

Return to Trial Database

GYN03-62

Imatinib Mesylate (Gleevec®, STI571) in Combination With Docetaxel (Taxotere) for the Treatment of Advanced, Platinum-Refractory Ovarian Cancer and Primary Peritoneal Carcinomatosis: Hoosier Oncology Group GYN03-62

Status

Study Completed

Cancer Type(s)

Ovarian

Study Contact

Publications

Clinical Activity of Imatinib Mesylate (Gleevec) In Combination with Docetaxel In Patients With Advanced, Platinum-Resistant Ovarian Cancer Or Primary Peritoneal Carcinomatosis
  • D Matei, RE Emerson, N Menning, J Schilder, J McClean, G Sutton, D Stephens, M Witherite, C Whalen, DH Moore
Imatinib Mesylate in Combination with Docetaxel for the Treatment of Advanced, Platinum-Resistant Ovarian Cancer and Primary Peritoneal Carcinomatosis
  • D Matei, RE Emerson, J Schilder, N Menning, LA Baldridge, CS Johnson, T Breen, J McClean, D Stephens, C Whalen, G Sutton

Trial Locations

All sites in which the trial GYN03-62 being conducted in.
No data was found
  • 7676 Interactive Way, Suite 120, Indianapolis, IN 46278